Olema Pharmaceuticals develops experimental oral drugs for breast cancer, based in San Francisco. It last closed at $7.22 on Nov 17, down 1.90% on the day.
Only 1 firm rated OLMA in the past 90 days, not enough for a consensus
Average 12-month target
$30.00
▲ 315.5% upside
Based on 1 analyst who set a price target on OLMA in the past 90 days. The average target is $30.00, with a high of $30.00 and a low of $30.00, compared with the last close of $7.22.
Low $30.00Avg $30.00High $30.00
Blue marker: last close $7.22
Highest target$30.00
Average target$30.00
Lowest target$30.00
Latest rating changes
StifelMaintained
Sep 14Buy$30
JP MorganMaintained
Aug 13Buy$46
CitigroupMaintained
Aug 11Buy$59
HC Wainwright & Co.Maintained
Aug 11Buy$36
Date
Firm
Action
Rating
Price target
Sep 14
Stifel
Maintained
Buy
$30
Aug 13
JP Morgan
Maintained
Buy
$46
Aug 11
Citigroup
Maintained
Buy
$59
Aug 11
HC Wainwright & Co.
Maintained
Buy
$36
Loading…
Technical Analysis
OLMA · as of the Nov 17 close · updated after every close
Downtrend
The stock sits between its 20 and 50 day averages. It is 79% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the Pivot at $7.20, and the nearest resistance the Pivot R1 at $7.38.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.7%/day
Key levels
$36.2652 week high+402.2%
$12.90200 day average+78.7%
$9.72100 day average+34.6%
$8.0450 day average+11.4%
$7.60Swing high (Oct 29)+5.3%
$7.38Pivot R1+2.2%
$7.2220 day average+0.0%
$7.22Last close
$7.20Pivot−0.3%
$7.04Pivot S1−2.5%
$6.71Swing low (Nov 5)−7.1%
$6.2452 week low−13.6%
Indicators
RSI (14)
46.06
Middle of its range
Neutral
MACD
-0.12
Above its signal line
Bullish
Stochastic
45.4
Middle of its range
Neutral
ADX (14)
20.8
Weak trend
Williams %R
-66.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
0.6
Oversold below −100, overbought above 100
Neutral
Rate of change
−1.8%
Change over 10 sessions
Bearish
ATR (14)
$0.55
Typical daily range, 7.7% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumFading
StretchNear oversold
VolatilityNormal, 19.9%/day
Key levels
$36.2652 week high+402.2%
$12.90200 day average+78.7%
$9.72100 day average+34.6%
$8.0450 day average+11.4%
$7.60Swing high (Oct 29)+5.3%
$7.38Pivot R1+2.2%
$7.2220 day average+0.0%
$7.22Last close
$7.20Pivot−0.3%
$7.04Pivot S1−2.5%
$6.71Swing low (Nov 5)−7.1%
$6.2452 week low−13.6%
Indicators
RSI (14)
34.53
Weak, oversold below 30
Neutral
MACD
-1.83
Below its signal line
Bearish
Stochastic
19.9
Near the bottom of its range
Oversold
ADX (14)
29.8
Trending down
Williams %R
-80.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-84.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−29.4%
Change over 10 sessions
Bearish
ATR (14)
$1.44
Typical daily range, 19.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for OLMA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OLMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow OLMA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How OLMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OLMA is in one of them and how their past OLMA trades turned out.
Olema Pharmaceuticals is a drug developer based in San Francisco, California. It is developing oral medicines for breast cancer, led by palazestrant, an experimental drug that blocks the estrogen receptor and breaks it down. The company is also developing OP3136, a treatment that targets the KAT6 protein. If approved, these drugs would be prescribed to women with breast cancer. None of its products are approved for sale yet, so it has no product sales.